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Abstract
Highly active antiretroviral therapy (HAART) can reduce levels of human immunodeficiency virus type 1 (HIV-1) to
undetectable levels in infected individuals, but the virus is not eradicated. The mechanisms of viral persistence during
HAART are poorly defined, but some reservoirs have been identified, such as latently infected resting memory CD4+ T cells.
During latency, in addition to blocks at the initiation and elongation steps of viral transcription, there is a block in the export
of viral RNA (vRNA), leading to the accumulation of multiply-spliced transcripts in the nucleus. Two of the genes encoded by
the multiply-spliced transcripts are Tat and Rev, which are essential early in the viral replication cycle and might indicate the
state of infection in a given population of cells. Here, the levels of multiply-spliced transcripts were compared to the levels
of gag-containing RNA in tissue samples from RT-SHIV-infected rhesus macaques treated with HAART. Splice site sequence
variation was identified during development of a TaqMan PCR assay. Multiply-spliced transcripts were detected in
gastrointestinal and lymphatic tissues, but not the thymus. Levels of multiply-spliced transcripts were lower than levels of
gag RNA, and both correlated with plasma virus loads. The ratio of multiply-spliced to gag RNA was greatest in the
gastrointestinal samples from macaques with plasma virus loads ,50 vRNA copies per mL at necropsy. Levels of gag RNA
and multiply-spliced mRNA in tissues from RT-SHIV-infected macaques correlate with plasma virus load.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) persists in
infected persons despite advancements in treatment. Current
treatment regimens, called highly active antiretroviral therapy
(HAART), usually consist of combinations of three or more drugs
from two or more classes of antiretroviral agents (reviewed in [1]).
HAART prevents progression to acquired immune deficiency
syndrome (AIDS) in many individuals who are able to obtain and
adhere to treatment regimens (reviewed in [1]). However,
intermittent detectable viremia and viral rebound upon cessation
of HAART demonstrate that the virus is not eradicated [2–6].
More sensitive virus load assays have demonstrated that low-level
viremia persists during HAART [7–10].
The sources of persistent virus and residual viremia have been
termed reservoirs, which have not been fully characterized.
Several mechanisms could be contributing to viral persistence,
including low-level viral replication or the persistence of long-lived
cells that release virus slowly or episodically [7,11,12]. Two
examples of long-lived cellular reservoirs that persist despite
HAART are macrophages and resting memory CD4+ T
lymphocytes [13–16]. Latently-infected resting memory CD4+ T
cells contain a provirus predicted to be replication competent but
express very little viral RNA (vRNA), resulting in non-productive
infection [17,18].
Although the exact mechanisms of viral latency have not yet
been elucidated, several transcription-based models have been
proposed [17,19]. Silencing of the provirus may occur if the viral
LTR is bound in inactive chromatin [20–24]. Another block to
viral transcription is overcome by the viral protein trans-activator
of transcription (Tat), which is encoded by multiply spliced viral
mRNA (MS mRNA) [25,26]. Tat is essential for viral replication
[27,28] and serves as a transcriptional anti-terminator [29] to
increase the steady-state levels of viral mRNA [30]. The viral
protein Rev is another essential viral protein encoded by MS
mRNA [31,32]. Rev binds to the Rev-response element (RRE) of
full-length and partially spliced vRNA and plays a role in its
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transport from the nucleus to the cytoplasm for translation and
packaging into virions [33,34]. Interestingly, in purified resting
memory CD4+ T cell populations from HAART-treated people an
abundance of MS viral mRNAs have been detected despite an
absence of cellular activation [35,36]. This suggests that blocks at
the transcriptional initiation and elongation steps are not absolute
and that some transcription occurs, even in latently infected cells
[35,36].
Non-human primate animal models of AIDS have been
developed and are being used to address viral persistence during
HAART [37–41]. Due to the specificity of the non-nucleoside RT-
inhibitors (NNRTIs) for HIV-1 reverse transcriptase (RT), some of
these models use RT-SHIV [37–39]. RT-SHIV is a chimeric virus
consisting of simian immunodeficiency virus mac239 with the
reverse transcriptase of HIV-1 HXBc2 [42,43]. Because RT-
SHIV infection of macaques models HIV-1 infection in humans
during HAART, it can be used to address questions of lentiviral
persistence that are not feasible in human studies.
Recently, our group analyzed the distribution of RT-SHIV
DNA and gag RNA in tissues collected at necropsy from macaques
treated with HAART [37]. Analysis of whole tissue lysates and
single-cell suspensions generated from those same tissues demon-
strated that viral DNA (vDNA) and gag RNA were widely
distributed in many tissues [37]. The results also suggested that
some gag RNA was lost during the preparation of the single-cell
suspensions [37]. It is not known whether this lost gag RNA was
present in infected cells that were lost during preparation of the
single-cell suspensions or contained in extracellular virions that
were washed away during the preparation of the single-cell
suspensions [37]. A previous study demonstrated that follicular
dendritic cells (FDCs) in tissues in SIV-infected macaques can
retain full-length vRNA, but not MS mRNA [44].
In the present study, we addressed the possibility that MS
transcripts might serve as indicators of viral persistence in tissues
from RT-SHIV-infected macaques during HAART. Levels of MS
transcripts might indicate newly infected cells because they are
essential early in the viral replication cycle, before the temporal
switch to production of full-length vRNA. MS mRNAs also
accumulate in the nucleus of latently-infected resting memory
CD4+ T cells [35,36]. We developed a two-step TaqMan real-time
RT-PCR assay for the quantification of MS transcripts in tissues
collected at necropsy. Levels of MS transcripts were compared
with levels of gag RNA in the same tissues to determine whether
productive viral infection or latency dominated in specific sites of
viral persistence. Some of the macaques also received a regimen of
valproic acid and prostratin as induction therapy designed to
activate latent virus in the presence of HAART.
Results
Variation at the Exon-One and Exon-Two Splice Junction
The plasmid TOPOtat was generated by cloning the MS
transcript from RT-SHIV infected CEMx174 cells into a TOPO
vector to serve as a DNA standard in the development of a
TaqMan real-time PCR assay for the quantification of the MS
transcript. Upon sequence analysis, plasmid clones containing
PCR-amplified MS transcripts from RT-SHIV-infected
CEMx174 cells demonstrated sequence variation at the coding
exon-one and coding exon-two splice junction (Table 1). The first
variant contained an additional three nucleotides (+CAG) that
were absent in the second variant (2CAG; Table 1 and Figure 1).
A third, minor variant was observed which contained a C-to-T
mutation (+TAG). While the viral envelope protein (Env) is also
encoded in this region, the env mRNA is not spliced at this site.
However, this codon is in frame and the observed C-to-T
Figure 1. Map of the MS mRNA splice site. Genome map depicting the MS transcript region of RT-SHIV. There are two open reading frames on
the MS transcript, encoding the Tat and Rev proteins. The Envelope protein (Env) is also encoded through this region. A portion of full-length viral
sequence surrounding the splice junction is displayed (blue bar with sequence below). The splice donor and the alternative acceptor sites for the MS
transcript are indicated with a red asterisk. A splicing event with splice acceptor 1 would result in a viral transcript containing the CAG sequence,
while an event with splice acceptor 2 would result in a transcript without the CAG sequence.
doi:10.1371/journal.pone.0087914.g001
MS mRNA in Tissues
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e87914
mutation would result in a stop codon (TAG) in the env reading
frame.
To determine whether this splice site sequence variation also
occurred in animals, MS transcripts were PCR-amplified from
several tissues from a monkey with a high plasma virus load (Mmu
36544; 1.296106 vRNA copies/mL) and subsequently cloned into
a TOPO vector (Table 1). These plasmid clones also demonstrated
sequence variation at the coding exon-one and coding exon-two
splice junction, with some clones being variant one (+CAG) while
others were variant two (2CAG; Table 1). None of the clones
contained the +TAG variant.
Splice site sequence variation in the cloned MS transcripts could
be the result of splicing event variation or mutations of either splice
acceptor G-8803 or G-8805 in the viral genome (GenBank
accession number M33262; Figure 1). The boundary region
between the intron and the MS transcript coding exon-two was
cloned into a TOPO vector and sequenced in order to determine
whether the variation was the result of mutations in the viral
genome (Table 2). Proviral DNA was amplified from peripheral
blood mononuclear (PBM) cells and mesenteric lymph node tissue
from animal Mmu 36544. Viral RNA was also cloned and
sequenced from PBM cells and plasma. Five or six clones were
sequenced for each sample to generate a total of 21 clones; all of
these clones contained the wild type RT-SHIV sequence through
the amplified region (Table 2).
Together, these results indicate that the observed sequence
variation is the result of splicing event variation rather than
mutations in the viral genome. These data also suggest that either
of the guanine nucleotides at positions 8803 and 8805 can serve as
coding exon-two splice acceptor sites, resulting in mRNA with or
without the CAG sequence, respectively (Figure 1). Chi-squared
analysis of the plasmid clones indicated a similar frequency in the
number of transcripts generated from either splice acceptor site.
Development of TaqMan PCR for Multiply Spliced
Transcripts
TOPOtat was used for standardization of TaqMan real-time
PCR in order to quantify the MS transcripts in tissues from RT-
SHIV-infected macaques. Serial ten-fold dilutions of the plasmids
TOPOtat-CAG and TOPOtat+CAG were used as templates in
TaqMan PCR to generate standard curves. Results of TaqMan
PCR using the SIVtat 284#2p probe (containing the CAG
sequence) were linear over seven logs, whether the template
contained the CAG nucleotides or not (Figure 2A). Linear
regression analysis resulted in slopes of 23.54 for the –CAG
template (r2 = 0.978) and –3.43 for the +CAG template
(r2 = 0.989), indicating amplification efficiencies of 92% and
96%, respectively. Because this single set of TaqMan primers
and probe detected both viral sequence variants efficiently, it was
used for all subsequent analysis in this study.
Initial screening of six different tissues from RT-SHIV-infected,
HAART-treated macaques demonstrated that MS mRNA levels
were below the level of detection of standard TaqMan PCR in
most samples (data not shown). To increase the sensitivity of the
assay, a 25 cycle multiplex PCR preamplification step was
developed. To test for linearity in the preamplification step, MS
mRNA, gag RNA and cellular GAPDH RNA were amplified from
total cDNA isolated from RT-SHIV-infected CEMx174 cells.
Samples were removed from the cycler every five cycles, through
25 cycles. TaqMan PCR for each target was used in single-plex
reactions to quantify copy numbers of RNA. Linear regression
analysis demonstrated that the preamplification step was linear
through 25 cycles for all three targets with r2 values for MS, gag,
and GAPDH RNA of 0.993, 0.980, and 0.995, respectively
(Figure 2B).
GAPDH RNA Levels in Tissues
GAPDH RNA in six different tissues from each of the animals
was quantified to determine whether this housekeeping gene could
be used to normalize viral RNA content. Multiplex preamplifica-
tion PCR was performed on cDNA generated from 4 mg of total
RNA isolated from tissues from all nine macaques. TaqMan PCR
of the preamplified cDNA demonstrated that GAPDH RNA levels
were similar in all tissues (Figure 2C). A one-way analysis of
variance (ANOVA) confirmed that the mean GAPDH RNA levels
of the tissues were not significantly different. These results indicate
that GAPDH RNA levels were consistent within this set of tissues,
and therefore could serve for standardization purposes.
Distribution of Viral RNA
Viral RNA was measured in plasma collected at necropsy from
all nine animals (Tables 3 and 4). Three of these animals had
plasma virus loads that were detectable by the standard virus load
assay (.50 vRNA copies/mL; Table 3) [45]. The other six
animals had plasma virus loads that were below the limit of
detection of the standard virus load assay (,50vRNA copies/mL;
Table 4). However, using a more sensitive virus load assay that
utilizes ultracentrifugation to concentrate virus from plasma [46],
low-level viremia was detected in three of these animals (Mmu
36348, Mmu 36166, and Mmu 36253; Table 4).
Table 1. Variants found at the MS mRNA splice sitea.
% of Clones
2CAG +CAG +TAG
CEMx174 cells 31 (4/13) 46 (6/13) 23% (3/13)
Jejunum 14 (1/7) 86 (6/7) 0
Spleen 36 (4/11) 64 (7/11) 0
Mes LNb 60 (6/10) 40 (4/10) 0
% of Total Tissue Clonesc 39 (11/28) 61 (17/28) 0
aPercent of plasmid clones displaying the indicated sequence at the coding
exon-one and coding exon-two splice junction, number of clones in
parenthesis.
bMesenteric lymph node.
cPercentage of total cDNA clones obtained from jejunum, spleen, and
mesenteric LN.
doi:10.1371/journal.pone.0087914.t001
Table 2. Sequence analysis of full-length viral genomes at the
MS mRNA coding exon-two splice acceptor sites.
Number of Clones
Wildtypea Mutationb
Plasma vRNA 5 0
PBM cell vRNA 5 0
PBM cell provirus 5 0
Mes LNc provirus 6 0
aWildtype sequence of RT-SHIV includes guanine at positions 8803 and 8805.
bA mutation at splice acceptor G-8803 would prevent the generation of a MS
transcript containing the CAG sequence.
cMesenteric lymph node.
doi:10.1371/journal.pone.0087914.t002
MS mRNA in Tissues
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RT-SHIV MS mRNA and gag RNA were quantified by
TaqMan real-time PCR as a measure of viral distribution in tissues
during HAART (Tables 3 and 4). Due to the low levels of these
transcripts on initial screening, the preamplification assay was used
prior to TaqMan quantification. To standardize the values, copies
of MS mRNA and gag RNA were normalized per 106 copies of
GAPDH RNA in each sample. Twenty-eight of the samples had
detectable gag RNA, but no detectable MS mRNA (Tables 3 and
4). MS transcripts in tissues from macaques with plasma virus
loads .50 vRNA copies/mL (Table 3) were detected more often
than in animals with plasma viral loads ,50 vRNA copies/mL
(Table 4), 10 out of 18 samples versus 6 out of 35 samples,
respectively. In two of the animals with plasma virus loads .50
vRNA copies/mL that received induction therapy, Mmu 36160
and 36353, the MS mRNA levels were below the level of detection
in several samples. Levels of gag RNA in tissues displayed a similar
pattern with generally higher levels detected in macaques with
plasma virus loads .50 vRNA copies/mL than in those with
plasma virus loads ,50 vRNA copies/mL. MS mRNA was not
detected in thymus samples from any of the macaques, despite
detectable gag RNA in some (Mmu 36544, Mmu 36160, Mmu
36353, and Mmu 36253; Tables 3 and 4).
To confirm the observation that higher plasma viral loads were
associated with higher levels of RNA in tissues, correlations of MS
mRNA and gag RNA to viral loads in plasma were determined
(Figure 3). Correlations were significant (P,0.0001) for both MS
mRNA and gag RNA for five of the tissues (duodenum, jejunum,
colon, spleen, and mesenteric lymph node), with Pearson r values
ranging from 0.9991 to 1.0000. Mmu 36544 had a plasma virus
load at necropsy of 1.296106 vRNA copies/mL (Table 3). This
plasma virus load is typical of untreated RT-SHIV-infected
macaques [37,38]. Nevertheless, we addressed the possibility that
this single animal was over-influencing the correlations by
excluding the data from that animal and re-assessing the
correlations. While the re-assessed correlations observed for gag
RNA to viral loads in plasma remained significant for all samples,
the MS mRNA correlations were only significant for spleen and
mesenteric lymph node samples (data not shown).
Comparison of Gastrointestinal Tissue vRNA with Viremia
To estimate whether tissues from animals treated with HAART
displayed an abundance of MS mRNA relative to gag RNA, the
ratios of MS mRNA levels to gag RNA levels were determined for
samples that had detectable levels of both RNAs (Figure 4). This
analysis was focused on duodenum, jejunum and colon samples
because only 2 of 12 mesenteric lymph node and spleen samples
had detectable levels of MS mRNA in macaques with well-
suppressed plasma virus loads (,50vRNA copies/mL) at necrop-
sy. An unpaired 2-tailed t-test demonstrated that the ratio of MS
mRNA to gag RNA in the macaques with plasma virus loads ,50
vRNA copies/mL was significantly higher than the ratio observed
in animals with plasma virus loads .50 vRNA copies/mL
(Figure 4, P=0.01).
Figure 2. Validation of TaqMan PCR for MS mRNA, multiplex
preamplification PCR, and distribution of GAPDH RNA in
macaque tissues. A) Vectors containing a portion of the MS transcript
with or without the CAG nucleotides at the coding exon-1 and coding
exon-2 splice junction were used as standards for real-time TaqMan
PCR. The plasmids were quantified by A260 spectrophotometric
readings and serially diluted for quantification by TaqMan PCR. Data
shown are the average threshold cycle (Ct) +/2 standard deviation of
triplicate experiments, with some standard deviations too small to
appear. The lines indicate regression analysis used to obtain line
equations for calculating the amplification efficiencies and for the
quantification of MS mRNA in samples. B) cDNA was generated from
total RNA from RT-SHIV-infected CEMx174 cells isolated 48 hours post-
infection using random hexamers primers. Multiplex preamplification
PCR was performed for viral MS mRNA and gag RNA in addition to the
cellular housekeeping gene GAPDH RNA. Individual reactions were
removed from the cycler every five cycles, followed by quantification of
the three transcripts by TaqMan PCR to determine whether the
preamplification step was linear. Data shown are the average +/2
standard deviation of triplicate experiments, with some standard
deviations too small to appear. The lines indicate regression analysis.
C) Total RNA was isolated from tissues and quantified by two-step
TaqMan RT-PCR. Total cDNA was preamplified for 25 cycles in multiplex
PCR before TaqMan PCR quantification. Cellular GAPDH RNA was
measured in these six tissues from all nine macaques in order to
determine whether it could serve as a standard. The solid symbols
indicate samples from animals that received only HAART while the open
symbols indicate samples from animals that received HAART plus
induction therapy. The horizontal lines represent the averages with 95%
confidence intervals.
doi:10.1371/journal.pone.0087914.g002
MS mRNA in Tissues
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Discussion
While it is apparent that HAART does not eradicate HIV-1
infection, reservoirs allowing for viral persistence during treatment
are poorly understood. To help elucidate the mechanisms of viral
persistence, we compared the distribution of viral MS mRNA and
gag RNA in tissues from RT-SHIV-infected macaques treated with
HAART. Due to the possibility that both low-level viral
replication and long-lived cellular reservoirs might persist despite
HAART, we elected to analyze total tissue lysates as opposed to
populations enriched for resting memory CD4+ T lymphocytes
[8,12,13,47–49]. Enrichment of specific populations of cells might
exclude other cells that are persistently infected or harboring virus.
A previous study utilizing in situ hybridization in tissues from SIV-
infected macaques demonstrated that gag RNA was more
prevalent than MS mRNA in the absence of HAART [44]. The
results presented here demonstrated that gag RNA was also present
at higher levels than MS mRNA in tissues from HAART-treated,
RT-SHIV-infected macaques.
During development of a TaqMan real-time PCR assay for
quantifying MS transcripts in tissues from RT-SHIV-infected
macaques, sequence variation at the MS mRNA coding exon-one
and coding exon-two splice junction was identified. Analysis of
genomic viral nucleic acids indicated that the observed splicing
difference is a consequence of differential splicing and not due to
mutations in the viral genome. Other groups have reported the
presence of alternative splice acceptors or sequence variation at
the coding exon-one and coding exon-two splice junction of MS
mRNA in several strains of SIV and cell culture systems [50–55].
To our knowledge, our report is the first to describe this alternative
splicing event in vivo. Our results from tissues support the general
pattern of splice acceptor usage previously described in the cell
culture experiments, with 39% of the 28 clones that we sequenced
utilizing the first splice acceptor and 61% utilizing the second
acceptor (Table 1). The functional effects of these variants on Tat
or Rev are not clear. Tat proteins expressed from cDNA clones of
the three variants observed by Viglianti et al. did not differ
significantly in trans-activation of SIVmac LTRs [51]. Whether
they differ in function in vivo is not known.
A similar pattern of three potential splice acceptors for coding
exon-two of tat and rev mRNA is present in the genomes of HIV-
1HXB2 [56] and HIV-1NL4-3 [57]. These splice acceptors were
designated SA7, SA7a, and SA7b [56]. Purcell et al. demonstrated
that only one of these three splice acceptors (SA7) is used for
coding exon-two of MS mRNA in HIV-1NL4-3-infected cells [57].
Table 3. MS mRNA and gag RNA analysis in macaques with plasma virus loads .50 vRNA copies/mL at necropsya.
Mmu 36544 Mmu 36160b Mmu 36353b
Plasma VL (vRNA copies/mL) 1,290,000 316 1,850
MS gag MS gag MS gag
Duodenum 101 10,100 ,0.06 7.1 2.0 60
Jejunum 55 13,700 ,0.06 ,0.06 ,0.06 24
Colon 299 119,000 1.1 773 ,0.06 11
Spleen 814 436,000 2.5 2,140 27 6,720
Thymus ,0.06 528 ,0.06 2.0 ,0.06 3.5
Mes LNc 357 103,000 ,0.06 125 1.1 370
aCopies of either MS mRNA or gag RNA per 106 copies of GAPDH RNA; ,0.06 indicates that the sample was below the limit of detection.
bAlso received induction therapy.
cMesenteric lymph node.
doi:10.1371/journal.pone.0087914.t003
Table 4. MS mRNA and gag RNA analysis in macaques with plasma virus loads ,50 vRNA copies/mL at necropsya.
Mmu 36348 Mmu 36166 Mmu 36253b Mmu 36661b Mmu 36349b Mmu 36488b
Plasma VL (vRNA
copies/mL) 11 25 5 ,3 ,50 ,50
MS gag MS gag MS gag MS gag MS gag MS gag
Duodenum ,0.06 5.8 3.9 19 ,0.06 ,0.06 2.5 40 ,0.06 1.3 ,0.06 1.6
Jejunum ,0.06 ,0.06 ,0.06 6.7 ,0.06 ,0.06 0.062 ,0.06 ,0.06 3.3 ,0.06 8.6
Colon ,0.06 6.1 ,0.06 18 3.83 39 ,0.06 13 ,0.06 ,0.06 ,0.06 584
Spleen ,0.06 1.8 ,0.06 29 ,0.06 18 ,0.06 34 ,0.06 24 0.11 104
Thymus ,0.06 ,0.06 NDd NDd ,0.06 6.2 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06 ,0.06
Mes LNc ,0.06 41 ,0.06 42 0.16 75 ,0.06 49 ,0.06 153 ,0.06 282
aCopies of either MS mRNA or gag RNA per 106 copies of GAPDH RNA; ,0.06 indicates that the sample was below the limit of detection.
bAlso received induction therapy.
cMesenteric Lymph Node.
dNot Determined.
doi:10.1371/journal.pone.0087914.t004
MS mRNA in Tissues
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It is not known whether other strains of HIV-1 utilize any of the
other splice acceptors.
The third variant that we observed in cDNA clones generated
from RT-SHIV-infected CEMx174 cells was not observed in any
of the clones generated from tissues. Kodama et al. previously
reported on the presence of premature stop codons in the
transmembrane domain of SIV env [58]. Our results support their
conclusion that the TAG variant is an in vitro artifact due to SIV
replication in unnatural human cells.
TaqMan quantification of MS mRNA from the HAART-
treated macaques indicated that no tissue had consistently
detectable levels of MS mRNA. Interestingly, MS mRNA was
not detected in any of the thymus samples despite detectable levels
of gag RNA in some. Because the gag RNA levels that were
detected were at lower levels than in the other tissues, it is possible
that viral replication or reactivation from latency is occurring in
the thymus but at levels too low to detect the MS mRNA.
However, the lack of MS mRNA suggested that the detected gag
RNA in thymus might be virion-associated or trapped in cells such
as FDCs [44]. These results support a previous study that
concluded that thymocytes are not a viral reservoir in SIV-infected
pig-tailed macaques treated with antiretroviral therapy [59].
MS mRNA and gag RNA levels from well-suppressed animals
(,50 vRNA copies/mL) were compared with the levels observed
in animals with higher virus loads (.50 vRNA copies/mL). While
none of the tissues contained an abundance of MS transcripts
relative to gag RNA, the gastrointestinal samples from well-
suppressed macaques had a significantly higher ratio of MS to gag
RNA, which suggests a state of viral latency in these samples. Two
recent studies by Yukl et al. analyzed biopsies taken from
gastrointestinal compartments of HIV-1-infected patients during
HAART [60,61]. In those studies, MS mRNA was not detected in
the gastrointestinal samples, but a preamplification step was not
employed [60,61]. However, biopsies taken from the large bowel
tended to have lower ratios of gag RNA to vDNA, suggesting viral
latency in these tissues despite high numbers of activated CD4+ T
cells [60,61]. Their results also suggested that the ileum tended to
have higher ratios, indicating active replication [60,61]. We did
not analyze ileum samples, but our results support their
conclusions that the other regions of the gut might be a potential
reservoir of latent virus during HAART. The preamplification step
Figure 3. MS mRNA and gag RNA levels correlate with plasma virus loads in macaques. The correlations were determined between
plasma virus loads and levels of the MS transcript (red circles) and gag RNA (blue squares) in tissues from infected macaques. The solid symbols
indicate samples from animals that received only HAART while the open symbols indicate samples from animals that received HAART plus induction
therapy. All nine animals from the study are represented in the figure. Both axes represent log RNA levels and the dashed line indicates the limit of
detection.
doi:10.1371/journal.pone.0087914.g003
Figure 4. Ratio of MS mRNA to gag RNA in gastrointestinal
tissues. The ratios of the MS transcript to gag RNA in duodenum,
jejunum, and colon were calculated in order to determine whether
there was an abundance of MS mRNA in tissues from macaques treated
with HAART. Bars indicate average with standard error of the mean.
Horizontal line indicates the results of an unpaired two-tailed student t-
test.
doi:10.1371/journal.pone.0087914.g004
MS mRNA in Tissues
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that was utilized in our study enabled the detection of low-level
MS mRNA. A future study designed to analyze specific cell-types
for MS and gag RNA content using a preamplification step may
help to further elucidate the state of infection in these tissues.
An accumulation of MS mRNA in several key lymphoid tissues
was not observed despite the essential role of MS transcripts early
in the infection cycle and evidence that MS mRNAs accumulate in
the nucleus of latently-infected cells [35,36]. The levels of MS
mRNA in tissues from these macaques were very low, many below
the level of detection. gag RNA, which serves as genomic vRNA as
well as mRNA for Gag and Pol proteins, was present at higher
levels in these tissues. Importantly, while gag RNA is present in
virions and can persist in FDCs in the absence of infection [44],
MS mRNA is a product of the splicing machinery within infected
cells. In RT-SHIV-infected rhesus macaques, levels of both MS
mRNA and gag RNA in tissues correlate with plasma virus load.
Materials and Methods
Animals and Infection
Nine juvenile, male Rhesus macaques (Macaca mulatta; Mmu)
from the retrovirus-free colony of the California National Primate
Research Center (CNPRC) were used. This study was approved
by the Association for the Assessment and Accreditation of
Laboratory Animal Care, International (AAALAC) accredited
University of California, Davis Institutional Care and Use
Committee (IACUC). The UC Davis IACUC has an Animal
Welfare Assurance on file with the Office of Laboratory Animal
Welfare (OLAW). Animals were administered 10 mg/kg body
weight ketamine-HCl (Parke-Davis, Morris Plains, NJ, USA)
intramuscularly when necessary for immobilization. Additionally,
analgesics were administered at the discretion of the CNPRC
veterinary staff in an effort to minimize all animal pain and
discomfort. Macaques were housed at the California National
Primate Research Center, which is fully accredited by the
Association for the Assessment and Accreditation of Laboratory
Animal Care (AAALAC). For housing, animals were maintained
in cages with 4 square feet of floor space, or 6 square feet if over
10 kg, and fixed perch bars in a temperature-controlled BSL-2+
vivarium with continuous monitoring of temperature and humid-
ity. Compatible animals were paired continuously or intermittently
(separated at night) whenever possible. All animals had visual and
auditory access to other macaques 24 hours per day. These
animals were fed a balanced commercial macaque chow (Purina
Mills, Gray Summit, MO) twice daily and fresh produce twice
weekly, with free access to water 24 hours per day. Supplemental
food was provided when clinically indicated. Environmental
enrichment was provided daily, included manipulanda (forage
boards, mirrors, puzzle feeders) and novel foodstuffs.
The endpoint of this study was set at a pre-specified timepoint as
part of the experimental design of the antiretroviral treatment
regimen (see Antiretroviral Drugs and Induction Treatment). All
macaques were humanely euthanized by overdose of sodium
pentobarbital (60 mg/kg) administered by the intravenous route
under ketamine sedation (10 mg/kg).
For infection of animals, stocks of RT-SHIV were prepared
from cell culture supernatants of CEMx174 cells transfected with
the two viral half-clone plasmids as previously described [38,62].
Prior to infection, virus stocks were sequenced and contained the
required T-to-C substitution at position 8 of the SIV tRNA primer
binding site [63]. Macaques were inoculated intravenously with
105 50% tissue culture infectious doses of RT-SHIV as previously
described [46].
Antiretroviral Drugs and Induction Treatment
RT-SHIV-infected rhesus macaques were treated with HAART
as previously described [37]. Briefly, all nine macaques were
treated with a HAART regimen beginning six weeks post-
infection, consisting of tenofovir (PMPA), emtricitabine (FTC),
and efavirenz (EFV; Sustiva). FTC and PMPA were provided by
Gilead Sciences (Foster City, CA, USA) and EFV was purchased
from a pharmacy. PMPA and FTC were administered subcuta-
neously, once daily. FTC was reconstituted in phosphate buffered
saline (pH 7.4) and administered at 16 mg/kg body weight.
PMPA was re-suspended in distilled water, buffered with NaOH to
pH 7.0 and delivered at 30 mg/kg body weight. EFV was
delivered orally at 200 mg per day in food, as previously described
[37,38]. Animals were monitored weekly for weight and the drug
doses were adjusted according to body weight. After 15 weeks of
therapy, the dose of PMPA was reduced to 15 mg/kg body weight
to avoid renal toxicity [64].
After 26 weeks of HAART, six of the HAART-treated
macaques were treated with prostratin and valproic acid for eight
weeks in addition to continuing HAART. During the fist two
weeks of the induction period, each animal received induction
treatment five times. Over the final six weeks of the induction
period, each animal received weekly treatment. Prostratin (Salvia
Sciences, Palo Alto, CA) was delivered to anesthetized animals at
0.1 mg/kg by infusion in saphenous or cephalic veins. Valproic
acid (Upsher-Smith Laboratories, Minneapolis MN) was delivered
orally at 120 mg/kg in two doses, the first dose being delivered by
orogastric intubation during anesthesia and the second being
delivered in food later the same day. After the induction period,
the animals were continued on HAART alone until euthanasia.
Complete details of the induction treatment, including pharma-
cokinetics, will be published elsewhere (P.A. Luciw, manuscript in
preparation).
After 41 weeks of HAART, four of the animals (Mmu 36348,
Mmu 36166, Mmu 36253, and Mmu 36661) were sedated with
ketamine-HCl and then humanely euthanized with a barbiturate
overdose by veterinary pathologists and staff at the CNPRC.
HAART was stopped in the remaining five animals (Mmu 36544,
Mmu 36160, Mmu 36353, Mmu 36349, and Mmu 36488) and
plasma vRNA was monitored for viral rebound. After 16–20
weeks without HAART, these animals were subsequently eutha-
nized.
Isolation of RNA
In order to protect RNA in tissues from degradation at
necropsy, sections of tissue were treated with Qiagen RNAlater
RNA Stabilization Reagent (Valencia, CA, USA) according to the
manufacturer’s protocol. Briefly, sections of tissue no greater than
0.5 cm per dimension were cut from tissues using sterile scalpels.
Tissues were then stored in RNAlater overnight at 4uC. The
following day they were transferred to 1.5 ml centrifuge tubes and
stored at 280uC until nucleic acid extraction.
Tissues were disrupted for isolation of RNA with QIAzol Lysis
Reagent (Qiagen) using a Qiagen TissueRuptor (a rotor-stator
homogenizer). Frozen samples were weighed and 700 mL of
QIAzol per 50 mg of tissue was added. The samples were chopped
with sterile scalpels and then disrupted using the TissueRuptor
with autoclaved, disposable probes to prevent carry-over contam-
ination. The lysates were separated into 700 mL aliquots before the
addition of 150 mL of chloroform (Sigma-Aldrich, St. Louis, MO,
USA), followed by 15 sec of vigorous shaking. After three minutes
at room temperature, the samples were centrifuged at 12,0006g at
4uC. The aqueous phase was removed from each sample for RNA
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isolation and the remainder of each lysate was saved for DNA
isolation (see below).
For RNA extraction, 1.5 volumes of molecular grade absolute
ethanol (Sigma) was added to the aqueous phase and the samples
were applied to Qiagen miRNeasy mini columns according to
manufacturer’s protocol. Two sequential DNase digestions using
the RNase-Free DNase Set (Qiagen) were performed on each
sample according to the on-column treatment procedure. RNA
was eluted from each column using 52 mL of molecular grade
water. The optical density of each sample was measured using a
spectrophotometer at 260 nm and the samples were diluted to
10 mg of RNA per 50 mL of molecular grade water. An additional
DNase treatment was performed using TURBO DNase (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturer’s
protocol. The RNA was then stored in aliquots at 280uC.
Viral RNA was also isolated from 140 mL of plasma using the
QIAamp Viral RNA Mini Kit (Qiagen) according to the
manufacturer’s instructions. The RNA was eluted in molecular
grade water and aliquots were stored at 280uC.
Isolation of DNA
DNA was isolated from the fraction of QIAzol lysates not used
for total RNA isolation. Purification of DNA was accomplished by
precipitation of genomic DNA from the organic phenol/chloro-
form phase of each lysate by adding 0.3 volumes of molecular
grade absolute ethanol (Sigma). Samples were centrifuged at
20006g for five minutes at 4uC to pellet the DNA, and the
supernatant was discarded. The DNA was washed twice with
700 mL of 0.1 M sodium citrate containing 10% ethanol with a
centrifugation step after each wash as described above. Next, the
DNA was washed with 75% ethanol, followed by another
centrifugation step. The DNA was then dissolved in 500–
1,400 mL of molecular grade water. The DNA solution was
sheared using a Qiagen QIAshredder according to manufacturer’s
instructions in order to reduce viscosity.
Construction of TOPOtat
A portion of the RT-SHIV MS transcript was cloned into a
vector to be used as a standard for the development of a real-time
TaqMan PCR assay. As a source for the MS transcripts,
CEMx174 were infected with RT-SHIV at a multiplicity of
infection of 0.01. Total RNA was isolated from the infected cells
48 hrs post-infection using Qiagen RNeasy columns according to
the manufacturer’s protocol. MS mRNA was amplified from the
total RNA preparations in a one-step RT-PCR using Invitrogen
SuperScript III Reverse Transcriptase (RT) and Platinum Taq
DNA polymerase (Invitrogen) with 45 cycles of amplification and
primers SIV tatF6616 and SIV tatR9157 (Table 5) at 200 nM
each. Because the primers also have binding sites in the full-length
viral genome, a short extension time of one minute was used to
selectively amplify a portion of the MS transcript (332 base pairs)
relative to the amplicon which would be produced from the viral
genome (2541 base pairs). The PCR products were analyzed by
agarose gel electrophoresis, and then cloned into pCRII-TOPO
using TA cloning (Invitrogen) according to the manufacturer’s
protocol to generate the vector TOPOtat. TOPOtat was
propagated in TOP10F’ Escherichia coli, purified using a Qiagen
Plasmid Maxi prep kit, and then the sequence was verified.
Sequencing of Viral Nucleic Acids
Due to sequence variation in TOPOtat at the splice site of the
MS transcript, viral cDNAs from various sources were cloned and
sequenced to determine whether the variation was splicing
variation or viral mutation. Preamplified cDNA from macaque
tissues (prepared as described below) were amplified by nested
PCR in order to generate amplicons suitable for TOPO-TA
cloning and subsequent sequencing. The preamplified cDNA PCR
product was diluted ten-fold and 1 mL was used as a template for
second round PCR with Advantage 2 DNA Polymerase
(Clonetech, Mountain View, CA, USA) using primers SIV MS
TranF6814 and SIV MS TranR9117 (Table 5) at 250 nM each.
Conditions for the second round reaction were: 95uC for 2 min,
followed by 30 cycles of 95uC for 20 s, 55uC for 20 s, and 72uC for
20 s and ending with an extension step at 72uC for 10 min. Second
round PCR amplification products were cloned into pCR2.1-
TOPO (Invitrogen), propagated in E. coli, and sequenced.
Nested PCR was used to amplify a portion of unspliced full-
length virus from plasma vRNA, RNA from infected PBM cells,
and DNA from PBM cells and mesenteric lymph node samples
from infected macaques. The region amplified for sequence
analysis included a portion of the Tat/Rev encoding region and
the intron, corresponding to bases 7980 through 8871 of
SIVmac239 genome (GenBank accession number M33262) [65].
First round PCR was performed with primers SIVmac239 8006
and SIV MS PreAmpR9127 at a concentration of 250 nM,
0.05 U/mL REDTaq DNA Polymerase (Sigma), and approxi-
mately 16106 cell equivalents of genomic DNA or 20 mL of
cDNA. First round reaction conditions were: 95uC for 2 min,
followed by 25 cycles of 95uC for 20 s, 55uC for 20 s, 72uC for
1 min and a final extension step at 72uC for 10 min. Second round
PCR was performed with primers SIVmac239 8510 and SIV MS
TranR9117 and 1 mL of a ten-fold dilution of the first round PCR
product. Second round reaction conditions were identical to those
of the first round, except that a 30 second extension time was used
and products were amplified for 30 cycles. PCR products were
cloned into pCR2.1-TOPO (Invitrogen), propagated in E. coli, and
submitted for sequence analysis at the UC Davis sequencing
facility.
Standardization of TaqMan PCR for MS Transcripts
TOPOtat was used as a standard for the development of a
TaqMan PCR assay for the detection of the MS transcripts. The
primers were designed to target both tat and rev mRNA. To avoid
detection of full-length unspliced vRNA or viral DNA, the probe
was designed to span the coding exon-one and coding exon-two
splice junction of the MS transcripts. For standardization, plasmid
DNA was quantified spectrophotometrically at 260 nm and copy
Table 5. Sequences of the PCR primers and the SIVtat
284#2p TaqMan probe.
Primer Sequence (59 R 39)
SIVmac239 8006 TAACTCCACAGTGACCAGTCTCATAGC
SIVmac239 8510 CTAACACCAAAGTGGAACAATGAGAC
SIV tatF6616 CATGCATTTCAGAGGCGG
SIV tatR9157 TATCTGCCAAGGCCAGGAG
SIV MS PreAmpF6801 AGAAGAAGAACTCCGAAAAAGGC
SIV MS PreAmpR9127 GCCTTCTCCACCGTCTCTTTC
SIV MS TranF6814 CGAAAAAGGCTAAGGCTAATACATCT
SIV MS TranR9117 CCGTCTCTTTCTTTGCCTTCTC
SIVtat 284 #2p aCTGCATCAAACAACAGACCCATATCCAACAGb
aFAM labeled nucleotide.
bTAMRA coupled nucleotide.
doi:10.1371/journal.pone.0087914.t005
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numbers were determined. Ten-fold serial dilutions of this stock
were used as templates in a 12 mL TaqMan PCR assay using
Applied Biosystems (ABI) Universal Master Mix (Carlsbad, CA,
USA) on an ABI 7900 cycler. The primers used were SIV MS
TranF6814 and SIV MS TranR9117 at 400 nM and the TaqMan
probe SIVtat284#2p was used at 80 nM (Table 5). Amplification
efficiency (E) was determined as previously described [66] using
the equation: E~10{1=slope{1.
Multiplex PCR Preamplification and TaqMan Analysis
TaqMan PCR was used to quantify MS mRNA, gag RNA, and
cellular GAPDH mRNA in total RNA from RT-SHIV-infected
CEMx174 cells and in tissues collected from macaques at
necropsy. cDNA was generated from total RNA using SuperScript
III RT, random hexamers, and RNase inhibitor (Invitrogen) as
previously described [37]. Due to the very low levels of viral
transcripts in macaques treated with HAART, a multiplex
preamplification PCR step was employed on the cDNA prior to
TaqMan quantification [37,67]. In the multiplex PCR, primers
specific for MS mRNA were used, SIV MS PreAmpF6801 and
SIV MS PreAmpR9127 (Table 5), in combination with primers
specific for gag and GAPDH as previously described [37]. After 25
cycles of PCR using Advantage 2 DNA polymerase, the
preamplification products were quantified using TaqMan PCR
in single-target reactions (single-plex). The threshold cycles (Ct)
obtained from the TaqMan PCR analysis were used to determine
the levels of MS mRNA using the standard equation obtained
from the TOPOtat standard curve. Viral gag and cellular GAPDH
RNA levels were also determined based on standard curves as
previously described [37,38,45]. Because the preamplification was
performed in multiplex reactions, the MS and gag RNA levels were
normalized by the preamplified GAPDH RNA levels for standard-
ization purposes.
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